Unnamed: 0,title,date,stock,sentiment
731063.0,96 Biggest Movers From Yesterday,2020-05-27 04:20:00-04:00,KMDA,neutral
731064.0,61 Stocks Moving In Tuesday's Mid-Day Session,2020-05-26 12:29:00-04:00,KMDA,neutral
731065.0,Stocks That Hit 52-Week Highs On Friday,2020-05-22 10:31:00-04:00,KMDA,neutral
731066.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,KMDA,neutral
731067.0,64 Biggest Movers From Yesterday,2020-05-22 05:26:00-04:00,KMDA,neutral
731068.0,Kamada shares are trading lower despite the company reporting better-than-expected  Q1 earnings results.,2020-05-18 11:26:00-04:00,KMDA,neutral
731069.0,Recap: Kamada Q1 Earnings,2020-05-18 07:18:00-04:00,KMDA,neutral
731070.0,"Kamada Q1 EPS $0.12 Beats $0.06 Estimate, Sales $33.290M Beat $30.120M Estimate",2020-05-18 07:03:00-04:00,KMDA,neutral
731071.0,"Earnings Scheduled For May 18, 2020",2020-05-18 04:21:00-04:00,KMDA,neutral
731072.0,"Kamada And Kedrion Biopharma Announce Global Collaboration For Development, Manufacturing And Distribution Of A Plasma-Derived Anti-SARS-CoV-2 (Coronavirus COVID-19) Polyclonal Immunoglobulin Product",2020-04-27 07:08:00-04:00,KMDA,neutral
731073.0,36 Stocks Moving in Monday's Pre-Market Session,2020-03-23 07:38:00-04:00,KMDA,neutral
731074.0,Kamada Shares On Watch; Co. On Mar. 11 Announced It Plans To Utilize Hyper-Immunoglobulin Technology As A Potential Coronavirus Treatment,2020-03-19 12:07:00-04:00,KMDA,positive
731075.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,KMDA,negative
731076.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,KMDA,negative
731077.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,KMDA,positive
731078.0,Kamada Says Plans To Initiate Development Of Anti-Coronavirus Polyclonal Immunoglobulin,2020-03-11 07:05:00-04:00,KMDA,neutral
731079.0,"Kamada Q4 EPS $0.13, Inline, Sales $32.071M Miss $33.04M Estimate",2020-02-12 07:15:00-05:00,KMDA,negative
731080.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-21 07:57:00-05:00,KMDA,neutral
731081.0,Kamada Announces $25M Private Placement With FIMI Opportunity Fund; Co. To Issue ~4.17M Shares To FIMI At $6/Share,2020-01-21 07:03:00-05:00,KMDA,positive
731082.0,"Kamada Sees Prelim. Q4 Sales $31.4M-$32.4M vs $35.4M Est., FY19 Sales $126.5M-$127.5M vs $130.47M Est.; Sees FY20 Sales $132M-$137M vs $121.51M Est.",2020-01-07 07:05:00-05:00,KMDA,neutral
731083.0,Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency,2019-12-16 07:04:00-05:00,KMDA,neutral
731084.0,Kamada Wins a 12 Year Supply Contract Which is Expected to Add $8-$10M of Annual Revenue,2019-12-09 07:05:00-05:00,KMDA,positive
731085.0,"Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel, Expects Revenue of $20-$30M Within Several Years of Launch",2019-12-02 07:04:00-05:00,KMDA,neutral
731086.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,KMDA,positive
731087.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,KMDA,neutral
731088.0,33 Stocks Moving In Monday's Mid-Day Session,2019-11-25 12:28:00-05:00,KMDA,neutral
731089.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,KMDA,neutral
731090.0,18 Stocks Moving In Monday's Pre-Market Session,2019-11-25 07:15:00-05:00,KMDA,neutral
731091.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,KMDA,positive
731092.0,66 Biggest Movers From Yesterday,2019-11-22 04:50:00-05:00,KMDA,neutral
731093.0,Kamada Reaffirms FY19 Sales Guidance Of $125M-$130M vs $128.91M Est.,2019-11-13 07:03:00-05:00,KMDA,neutral
731094.0,"Kamada Q3 EPS $0.14 Beats $0.07 Estimate, Sales $33.1M Beat $28.92M Estimate",2019-11-13 07:02:00-05:00,KMDA,neutral
731095.0,Kamada and Kedrion Biopharma Highlights Publication Of Results From Registration Study Of KEDRAB In Human Vaccines & Immunotherapeutics Medical Journal,2019-10-29 08:13:00-04:00,KMDA,neutral
731096.0,Kamada Announces Extension Of GLASSIA Supply Agreement With Takeda,2019-09-03 07:03:00-04:00,KMDA,positive
731097.0,Kamada Earlier Reported Talks With Takeda Related To Potential Extension Of Period For Transition Of GLASSIA Manufacturing To Takeda,2019-08-08 10:28:00-04:00,KMDA,neutral
731098.0,"Kamada Q2 EPS $0.15 Beats $0.14 Estimate, Sales $35.3M Beat $34.37M Estimate",2019-08-06 07:27:00-04:00,KMDA,neutral
731099.0,Cannabics Pharmaceuticals Gets New Directors,2019-06-28 16:04:00-04:00,KMDA,neutral
731100.0,26 Stocks Moving In Tuesday's Pre-Market Session,2019-05-14 08:02:00-04:00,KMDA,neutral
731101.0,"Earnings Scheduled For May 14, 2019",2019-05-14 04:57:00-04:00,KMDA,neutral
731102.0,A Preview Of Kamada's Q1 Earnings,2019-05-13 14:44:00-04:00,KMDA,neutral
731103.0,Kamada Shares Resume Trade,2019-04-16 07:30:00-04:00,KMDA,positive
731104.0,Kamada Ltd. Shares To Resume Trade At 7:30 a.m. EDT,2019-04-16 07:18:00-04:00,KMDA,positive
731105.0,Kamada announces FDA Acceptance Of Inhaled AAT Program Path Forward,2019-04-16 07:02:00-04:00,KMDA,positive
731106.0,"Kamada Shares Halted, News Pending",2019-04-16 06:59:00-04:00,KMDA,positive
731107.0,26 Stocks Moving In Tuesday's Pre-Market Session,2019-02-12 08:25:00-05:00,KMDA,neutral
731108.0,"Kamada Reports Q4 EPS Of $0.44 May Not Compare To $0.18 Estimate, Sales $48.2M Beat $41.37M Est.; Reiterates FY19 Revenue Guidance Of $125M-130M vs $127.82M Est.",2019-02-12 06:13:00-05:00,KMDA,neutral
731109.0,"Earnings Scheduled For February 12, 2019",2019-02-12 04:02:00-05:00,KMDA,neutral
731110.0,UPDATE: Kamada Sees Top-Line Results For Phase 2 Intravenous Alpha-1 Antitrypsin Trial In 2H'2019,2019-02-06 07:25:00-05:00,KMDA,neutral
731111.0,"UPDATE: Kamada Reports 'IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test'",2019-02-06 07:25:00-05:00,KMDA,positive
731112.0,Kamada Reports Added Interim Results From Phase 2 Proof-Of-Concept Trial Of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection,2019-02-06 07:25:00-05:00,KMDA,negative
731113.0,Kamada Reaffirms FY19 Sales Guidance Of $125M-$130M vs $127.82M Est.,2019-01-02 07:03:00-05:00,KMDA,neutral
731114.0,Kamada Sees Q4 Sales $46.7M-$48.7M vs $39.37M Est. FY18 Sales $113M-$115M vs $105.88M Est.,2019-01-02 07:03:00-05:00,KMDA,neutral
731115.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,KMDA,neutral
731116.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,KMDA,neutral
731117.0,"Kamada Ltd. Q3 EPS $(0.06) Misses $(0.01) Estimate, Sales $14.975M Miss $18.13M Estimate",2018-11-12 07:08:00-05:00,KMDA,negative
731118.0,"Earnings Scheduled For November 12, 2018",2018-11-12 04:19:00-05:00,KMDA,neutral
731119.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,KMDA,neutral
731120.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,KMDA,neutral
731121.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,KMDA,neutral
731122.0,Kamada Announces Extension Of Collaboration With Massachusetts General Hospital For Proof-Of-Concept Study Evaluating Potential Benefit Of Liquid Alpha-1 Antitrypsin On Liver Preservation Prior To Transplantation,2018-09-05 07:07:00-04:00,KMDA,positive
731123.0,Kamada Cuts FY18 Sales Guidance From $116M-$120M To $102M-$108M; Co. Says Cut Is Due To Delayed Planned Product Shipments As A Result Of Recently Settled Labor Strike,2018-08-29 07:06:00-04:00,KMDA,negative
731124.0,Kamada Is Unable To Reaffirm 2018 Revenue Guidance Due To Ongoing Labor Strike At Co.'s Production Facility,2018-08-07 07:23:00-04:00,KMDA,negative
731125.0,"Kamada Q2 EPS $0.14 Beats $0.09 Estimate, Sales $33.8M Beat $30.6M Estimate",2018-08-07 07:21:00-04:00,KMDA,neutral
731126.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,KMDA,neutral
731127.0,"Kamada Receives Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT, Co. Plans to Submit Clinical Trial Application; Intends to Engage in Commercialization Discussions for A Strategic European Partner",2018-07-10 07:06:00-04:00,KMDA,positive
731128.0,Kamada Sees FY18 Sales $116-$120M vs $120.6M Est.,2018-05-15 07:05:00-04:00,KMDA,neutral
731129.0,"Kamada Ltd. - Ordinary Shares Q1 EPS $0.03 Beats $0.02 Estimate, Sales $17.441M Miss $24.02M Estimate",2018-05-15 07:05:00-04:00,KMDA,positive
731130.0,"Earnings Scheduled For May 15, 2018",2018-05-15 04:12:00-04:00,KMDA,neutral
731131.0,"Kamada, Kedrion Biopharma Report LAunch Of KEDRAB Rabies Immune Globulin In US, Initial Shipments Are Now Reaching Healthcare Practitioners",2018-05-08 07:46:00-04:00,KMDA,positive
731132.0,"Kamada Reports that the FDA Has Continued Safety Concerns for AAT, Kamada No Longer Expects to Initiate its Phase 3 Trial in 2H 2018",2018-04-23 07:10:00-04:00,KMDA,positive
731133.0,"Kamada Halted, News Pending",2018-04-23 06:58:00-04:00,KMDA,neutral
731134.0,"Kamada Reports Q4 EPS $0.16 vs $0.08 Est., Sales $35.7M vs $33.0M Est.",2018-02-07 07:23:00-05:00,KMDA,neutral
731135.0,"Benzinga's Top Upgrades, Downgrades For February 2, 2018",2018-02-02 09:35:00-05:00,KMDA,positive
731136.0,"Chardan Capital Initiates Coverage On Kamada with Buy Rating, Announces $7.00 Price Target",2018-02-02 06:18:00-05:00,KMDA,neutral
731137.0,"Kamada Shares Up 1% On Light Volume; Co. Earlier Offered Interim Results From Phase 2 Trial Of IV Alpha-1 Antitrypsin Treatment, Showed 'Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment'",2018-01-08 11:47:00-05:00,KMDA,positive
731138.0,Kamada Reports Collaboration With Consortium Of Prominent Hospitals For Evaluation Of Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease,2018-01-04 07:15:00-05:00,KMDA,positive
731139.0,Kamada Wins $13M 3 Year Supply Agreement from KamRAB,2017-11-21 07:08:00-05:00,KMDA,positive
731140.0,Kamada and Chiesi Farmaceutici Mutually Agree to Terminate Their European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency,2017-11-20 07:09:00-05:00,KMDA,positive
731141.0,Kamada Sees FY18 Sales $116M to $120M vs $121M Est.,2017-11-13 06:37:00-05:00,KMDA,neutral
731142.0,Kamada Reaffirms FY 2017 Guidance,2017-11-13 06:35:00-05:00,KMDA,neutral
731143.0,"UPDATE: Kamada Reports Q3 Adj. EPS $(0.00) vs $0.02 Est., Sales $22.9M vs $25.0M Est.",2017-11-13 06:35:00-05:00,KMDA,neutral
731144.0,"Earnings Scheduled For November 13, 2017",2017-11-13 03:15:00-05:00,KMDA,neutral
731145.0,"UPDATE: Kamada On Phase 2 Results Of Alpha-1 Antitrypsin: 'Efficacy trend was demonstrated in the pre-determined sub group of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg'",2017-11-01 08:14:00-04:00,KMDA,neutral
731146.0,Kamada 8-K Shows Top-Line Results From Phase 2 Trial Of Alpha-1 Antitrypsin For Newly-Diagnosed Type-1 Diabetes Patients: 'No significant treatment effect was observed in the overall study population',2017-11-01 08:13:00-04:00,KMDA,negative
731147.0,Secondary Offering Lockup Expirations Today For Karmada and Actinum Pharma,2017-10-26 09:08:00-04:00,KMDA,neutral
731148.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,KMDA,positive
731149.0,13 Stocks Moving In Wednesday's After-Hours Session,2017-10-18 17:38:00-04:00,KMDA,neutral
731150.0,"Kamada CEO and CFO to Step Down, Announces Chaime Orlev CFO",2017-09-18 07:09:00-04:00,KMDA,neutral
731151.0,13D Filing Shows Brosh Capital Reporting 4.7% Stake In Kamada,2017-09-13 15:03:00-04:00,KMDA,neutral
731152.0,FDA Issued Letter to Kamada Stating that it Continues to have Concerns and Questions about Safety and Efficacy of Inhaled AAT -6K,2017-08-28 15:45:00-04:00,KMDA,positive
731153.0,18 Biggest Mid-Day Gainers For Friday,2017-08-25 12:17:00-04:00,KMDA,neutral
731154.0,Mid-Morning Market Update: Markets Open Higher; Big Lots Profit Tops Estimates,2017-08-25 10:09:00-04:00,KMDA,positive
731155.0,22 Stocks Moving In Friday's Pre-Market Session,2017-08-25 08:02:00-04:00,KMDA,neutral
731156.0,"Kamada Shares Resume, Now Up 23%",2017-08-25 07:30:00-04:00,KMDA,positive
731157.0,"Kedrion Biopharma, Kamada Report Received FDA Approval Of KEDRAB For Post-Exposure Prophylaxis Against Rabies Infection",2017-08-25 07:00:00-04:00,KMDA,positive
731158.0,Kamada Halted News Pending,2017-08-25 06:57:00-04:00,KMDA,neutral
731159.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,KMDA,neutral
731160.0,"Kamada Q2 EPS $0.13 vs $0.12 Est., Sales $32.5M vs $33.2M Est.",2017-08-01 06:40:00-04:00,KMDA,neutral
731161.0,20 Biggest Mid-Day Losers For Friday,2017-07-28 13:09:00-04:00,KMDA,negative
731162.0,Kamada Prices ~3.33M Share Common Stock Offering At $4.50/Share,2017-07-28 09:28:00-04:00,KMDA,positive
731164.0,Kamada Pre-Announces Q2 Sales Of $32.5M vs $33.1M Est.,2017-07-27 16:35:00-04:00,KMDA,neutral
731165.0,Kamada Reports Submission Of Proposed Phase 3 Protocol To FDA For Inhaled Alpha-1 Antitrypsin For Treatment Of Alpha-1 Antirypsin Deficiency Disease,2017-07-20 07:11:00-04:00,KMDA,neutral
731166.0,Kamada Files to Offer Up to $100M in Shares -F3,2017-07-13 06:10:00-04:00,KMDA,positive
731168.0,Mid-Afternoon Market Update: Steelcase Tumbles Following Disappointing Earnings Report; Staples Shares Surge,2017-06-22 14:32:00-04:00,KMDA,negative
731169.0,11 Biggest Mid-Day Losers For Thursday,2017-06-22 12:54:00-04:00,KMDA,negative
731170.0,Mid-Day Market Update: Oracle Surges On Earnings Beat; Kamada Shares Plummet,2017-06-22 12:01:00-04:00,KMDA,positive
731171.0,Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings,2017-06-22 10:09:00-04:00,KMDA,neutral
731172.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-06-22 08:07:00-04:00,KMDA,neutral
731173.0,"Kamada Shares Resume, Now Down 20%",2017-06-22 07:32:00-04:00,KMDA,positive
731174.0,Kamada Shares To Resume Trade At 7:30 a.m. EDT,2017-06-22 07:25:00-04:00,KMDA,positive
731175.0,Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin,2017-06-22 07:00:00-04:00,KMDA,neutral
731176.0,"Kamada Halted, News Pending",2017-06-22 06:57:00-04:00,KMDA,neutral
731177.0,Kamada Announces Milestone Payment from Shire for GLASSIA,2017-06-12 07:03:00-04:00,KMDA,neutral
731178.0,15 Biggest Mid-Day Losers For Wednesday,2017-06-07 12:52:00-04:00,KMDA,negative
731179.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-06-07 08:05:00-04:00,KMDA,neutral
731180.0,25 Stocks Moving In Monday's Pre-Market Session,2017-06-05 08:07:00-04:00,KMDA,neutral
731181.0,18 Biggest Mid-Day Gainers For Thursday,2017-06-01 12:41:00-04:00,KMDA,neutral
731182.0,Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 AATD Conference,2017-05-24 06:33:00-04:00,KMDA,neutral
731183.0,Kamada Sees FY 2017 Sales $100M vs $101M Est,2017-05-16 07:12:00-04:00,KMDA,neutral
731184.0,"Kamada Q1 EPS $(0.11) vs $(0.03) Est, Sales $11.6M vs $20.77M Est",2017-05-16 07:11:00-04:00,KMDA,neutral
731185.0,Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation,2017-02-21 06:36:00-05:00,KMDA,positive
731186.0,"Kamada Q4 EPS $(0.05) vs $0.01 Est, Revenue $77.49M",2017-02-06 06:38:00-05:00,KMDA,neutral
731187.0,"Kamada Reports Q3 EPS $(0.14) vs. Est. $(0.07), Rev. $19.4M vs. Est. $19.8M",2016-11-10 07:23:00-05:00,KMDA,neutral
731188.0,"Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment, Has PDUFA Goal Date Of Aug. 29th 2017",2016-11-07 07:10:00-05:00,KMDA,positive
731189.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-11-01 08:32:00-04:00,KMDA,neutral
731190.0,12 Biggest Mid-Day Gainers For Thursday,2016-10-06 12:55:00-04:00,KMDA,neutral
731191.0,Stocks Hitting 52-Week Highs,2016-10-06 10:15:00-04:00,KMDA,neutral
731192.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-06 08:43:00-04:00,KMDA,neutral
731193.0,"Kamada Reports Extension of GLASSIA Supply, Distribution Deal with Shire, Has Minimum of $237M in Sales Over FY17-FY20",2016-10-06 06:32:00-04:00,KMDA,neutral
731194.0,H.C. Wainwright Talks Kamada's Recent Phase 2 Results,2016-09-01 09:32:00-04:00,KMDA,neutral
731195.0,Kamada and Kedrion Submit Biological License Application With FDA For Rabies Treatment,2016-09-01 06:30:00-04:00,KMDA,neutral
731196.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-30 12:51:00-04:00,KMDA,neutral
731197.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-08-30 08:24:00-04:00,KMDA,neutral
731198.0,A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Consumer Confidence Report,2016-08-30 07:39:00-04:00,KMDA,positive
731199.0,Kamada's Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint,2016-08-30 07:36:00-04:00,KMDA,neutral
731200.0,Kamada Says Meets Primary Endpoint Of U.S. Phase 2 Study Of Inhaled Alpha-1 Antitrypsin for Treatment Of Alpha-1 Antitrypsin Deficiency,2016-08-30 06:34:00-04:00,KMDA,neutral
731201.0,Kamada Sees FY 2016 Revenue $75M to $80M vs $78.5M est,2016-08-02 06:56:00-04:00,KMDA,neutral
731202.0,"Kamada Q2 EPS ($0.04) vs ($0.04) est, Revenue $19.1M vs $18.5M est",2016-08-02 06:56:00-04:00,KMDA,neutral
731203.0,Kamada Reports Collaboartion to Provide Early Access Throughout Europe to Alpha-1 Antitrypsin to Treat Bone Marrow Transplant Patients,2016-05-25 06:31:00-04:00,KMDA,positive
731204.0,"Kamada Q1 EPS ($0.06) vs ($0.06) est, Revenue $14.8M vs $15.1M est",2016-05-09 06:31:00-04:00,KMDA,neutral
731205.0,"Kamada Reports Received Two Milestone Payments Under Strategic Deals with Chiesi Farmaceutici, Baxalta",2016-05-02 07:14:00-04:00,KMDA,neutral
731206.0,Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin,2016-04-06 07:00:00-04:00,KMDA,neutral
731207.0,Kamada Submits Marketing Application to Europe For Alpha-1 Antitrypsin Deficiency,2016-03-28 06:32:00-04:00,KMDA,neutral
731208.0,Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as Post-Exposure Treatment,2015-12-23 06:03:00-05:00,KMDA,positive
731209.0,Kamada Reports Q3 ($0.13) Vs ($0.04),2015-11-10 07:04:00-05:00,KMDA,neutral
731210.0,Kamada Sees FY15 Rev. $70-$73M  vs. Est. $72.21M,2015-11-10 07:01:00-05:00,KMDA,neutral
731211.0,"Kamada Reports Q3 EPS $(0.13) vs. Est. $(0.04), Rev. $16.069M vs. Est. $18.67M",2015-11-10 07:01:00-05:00,KMDA,neutral
731212.0,Kamada Reports Third Extension of Strategic Agreement with Baxalta,2015-10-16 07:00:00-04:00,KMDA,positive
731213.0,"Kamada Affirms Revenue Projection For The First Half of 2015 At $28M; As A Result, Affirms FY15 Guidance",2015-07-08 07:03:00-04:00,KMDA,neutral
731214.0,"Kamada Awarded Key New Patent for Inhaled AAT, eFlow Nebulizer System in Israel",2015-07-01 07:02:00-04:00,KMDA,positive
731215.0,Kamada Announces Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency,2015-05-20 09:09:00-04:00,KMDA,positive
731216.0,Kamada Posts Q1 Loss,2015-05-12 08:14:00-04:00,KMDA,negative
731217.0,"Kamada Reports Q1 Loss $0.15 Vs Exp $0.03, Revs $8.93 Vs $16.12M",2015-05-12 07:06:00-04:00,KMDA,negative
731218.0,"Earnings Scheduled For May 12, 2015",2015-05-12 04:10:00-04:00,KMDA,neutral
731219.0,Kamada Announces  Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency,2015-04-20 06:07:00-04:00,KMDA,positive
731220.0,Morning Market Gainers,2015-03-23 09:56:00-04:00,KMDA,neutral
731221.0,Benzinga's Top #PreMarket Gainers,2015-03-23 08:07:00-04:00,KMDA,positive
731222.0,Kamada Announces European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease,2015-03-23 07:37:00-04:00,KMDA,positive
731223.0,"Kamada Announces Eran Schenker VP, Medical Director",2015-03-11 07:02:00-04:00,KMDA,neutral
731224.0,Morning Market Gainers,2015-02-02 09:44:00-05:00,KMDA,neutral
731225.0,Benzinga's Top #PreMarket Gainers,2015-02-02 08:17:00-05:00,KMDA,positive
731226.0,"Kamada Announces Update For Phase 2 and 3 Trial, Says Encouraged",2015-01-07 07:08:00-05:00,KMDA,positive
731227.0,Stocks Hitting 52-Week Lows,2014-11-12 10:35:00-05:00,KMDA,negative
731228.0,Morning Market Losers,2014-11-12 09:46:00-05:00,KMDA,negative
731229.0,Benzinga's Top #PreMarket Losers,2014-11-12 08:17:00-05:00,KMDA,negative
731230.0,"Earnings Scheduled For November 12, 2014",2014-11-12 04:54:00-05:00,KMDA,neutral
731231.0,FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease ,2014-10-29 08:38:00-04:00,KMDA,positive
731232.0,Stocks Hitting 52-Week Lows,2014-10-14 10:22:00-04:00,KMDA,negative
731233.0,Kamada Extends Strategic Agreement with Baxter ,2014-09-29 06:35:00-04:00,KMDA,positive
731234.0,Morning Market Losers ,2014-09-09 09:48:00-04:00,KMDA,negative
731235.0,Benzinga's Top #PreMarket Losers,2014-09-09 08:16:00-04:00,KMDA,negative
731236.0,Stocks Hitting 52-Week Lows,2014-09-08 10:14:00-04:00,KMDA,negative
731237.0,Morning Market Losers ,2014-09-08 09:48:00-04:00,KMDA,negative
731238.0,Benzinga's Top #PreMarket Losers,2014-09-08 08:18:00-04:00,KMDA,negative
731239.0,"Midday Losers From Thursday, September 4",2014-09-04 13:36:00-04:00,KMDA,negative
731240.0,Stocks Hitting 52-Week Lows,2014-09-04 10:09:00-04:00,KMDA,negative
731241.0,Morning Market Losers ,2014-09-04 09:44:00-04:00,KMDA,negative
731242.0,Benzinga's Top #PreMarket Losers,2014-09-04 08:10:00-04:00,KMDA,negative
731243.0,Shares Of Kamada Down Over 20%,2014-09-04 07:39:00-04:00,KMDA,positive
731244.0,Kamada Resumes Trading Down over 4%,2014-09-04 07:30:00-04:00,KMDA,neutral
731245.0,Kamada Shares To Resume Trading At 07:30AM EDT,2014-09-04 07:15:00-04:00,KMDA,positive
731246.0,UPDATE: Kamada to Discuss With FDA US Path for Registration;  Continues With Plans for EMA Submission ,2014-09-04 07:11:00-04:00,KMDA,neutral
731247.0,UPDATE: Kamada Says First AAT Deficiency Treatment to Show Impact on Lung Function,2014-09-04 07:09:00-04:00,KMDA,neutral
731248.0,PREVIEW: Kamada to Resume Trading at 7:30AM ET,2014-09-04 07:07:00-04:00,KMDA,neutral
731249.0,Kamada Says Did Not Achieve Primary Endpoints For Phase 2 And 3 For Alpha-1 Antitrypsin,2014-09-04 07:04:00-04:00,KMDA,neutral
731250.0,Kamada Halted,2014-09-04 06:58:00-04:00,KMDA,neutral
731251.0,Kamada to Announce results From Phase 2/3 Trials of Inhaled AAT,2014-09-03 16:30:00-04:00,KMDA,neutral
731252.0,Kamada Ltd. Reports Q2 EPS of $(0.23) vs $(0.02) Est; Revenue of $15.80M vs $17.17M Est,2014-08-14 08:06:00-04:00,KMDA,neutral
731253.0,Benzinga's Top #PreMarket Losers,2014-06-26 08:22:00-04:00,KMDA,negative
731254.0,Stocks Hitting 52-Week Lows,2014-06-24 10:27:00-04:00,KMDA,negative
731255.0,Stocks Hitting 52-Week Lows,2014-06-23 10:25:00-04:00,KMDA,negative
731256.0,Benzinga's Top #PreMarket Losers,2014-05-21 08:22:00-04:00,KMDA,negative
731257.0,Morning Market Losers ,2014-05-19 09:54:00-04:00,KMDA,negative
731258.0,Benzinga's Top #PreMarket Losers,2014-05-19 08:13:00-04:00,KMDA,negative
731259.0,Stocks Hitting 52-Week Lows ,2014-05-16 10:07:00-04:00,KMDA,negative
731260.0,Benzinga's Top #PreMarket Losers,2014-05-16 08:10:00-04:00,KMDA,negative
731261.0,Kamada to Announce Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat AATD on May 16 ,2014-05-15 05:30:00-04:00,KMDA,positive
731262.0,Kamada Announces Significantly Improved Infusion Rate for Glassia,2014-04-24 08:07:00-04:00,KMDA,positive
731263.0,Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split,2014-04-03 12:41:00-04:00,KMDA,positive
731264.0,Morning Market Movers ,2014-04-03 09:42:00-04:00,KMDA,neutral
731265.0,Kamada Announces US POC Study with Glassia to Treat GVHD,2014-04-03 07:09:00-04:00,KMDA,positive
731266.0,Kamada Initiaties Phase 2 US Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency ,2014-03-24 07:07:00-04:00,KMDA,positive
731267.0,Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May ,2014-03-21 07:10:00-04:00,KMDA,positive
731268.0,Benzinga's Top #PreMarket Losers,2014-03-06 08:16:00-05:00,KMDA,negative
731269.0,Kamada Reports Q4 EPS of $0.04 vs $0.05 Est; Revenue of $24.40M vs $25.22M Est,2014-02-05 06:35:00-05:00,KMDA,neutral
731270.0,Kamada Ltd. Reports Q2 EPS of $0.03 vs $0.01 Est; Revenue of $16.10M vs $16.30M Est,2013-08-01 08:10:00-04:00,KMDA,neutral
731271.0,UPDATE: Jefferies Initiates  Kamada at Buy on Solid Foundation,2013-06-25 11:13:00-04:00,KMDA,positive
731272.0,UPDATE: Oppenheimer Initiates Kamada at Outperform on Pioneering Inhaled Delivery with AAT Treatment,2013-06-25 09:35:00-04:00,KMDA,neutral
731273.0,"Jefferies Initiates Coverage on Kamada Ltd. at Buy, Announces $15.00 PT",2013-06-25 08:24:00-04:00,KMDA,neutral
731274.0,Benzinga's Top Initiations,2013-06-25 08:03:00-04:00,KMDA,positive
731275.0,Morgan Stanley Initiates Coverage on Kamada Ltd. at Equal-weight,2013-06-25 07:21:00-04:00,KMDA,neutral
731276.0,"Oppenheimer Initiates Coverage on Kamada Ltd. at Outperform, Announces $14.00 PT",2013-06-25 07:20:00-04:00,KMDA,neutral
731277.0,Kamada Granted Two Key Patents ,2013-06-24 08:11:00-04:00,KMDA,positive
731278.0,Shares of Kamada Open for Trade at $9.71/Share After Pricing at $9.25,2013-05-31 11:01:00-04:00,KMDA,positive
731279.0,"Shares of Kamada to Open for Quote at 10:45AM EDT, to Open for Trade at 11AM",2013-05-31 10:07:00-04:00,KMDA,positive
731280.0,"Kamada Ltd. Prices 5.58M shares at $9.25/Share, Stock Will Begin Trading Today",2013-05-31 08:09:00-04:00,KMDA,positive
